383 related articles for article (PubMed ID: 1727487)
21. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
Mulligan MJ; Ritter GD; Chaikin MA; Yamshchikov GV; Kumar P; Hahn BH; Sweet RW; Compans RW
Virology; 1992 Mar; 187(1):233-41. PubMed ID: 1736526
[TBL] [Abstract][Full Text] [Related]
23. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.
McKeating J; Balfe P; Clapham P; Weiss RA
J Virol; 1991 Sep; 65(9):4777-85. PubMed ID: 1870202
[TBL] [Abstract][Full Text] [Related]
24. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
Groenink M; Moore JP; Broersen S; Schuitemaker H
J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
[TBL] [Abstract][Full Text] [Related]
25. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
Moore JP
AIDS; 1990 Apr; 4(4):297-305. PubMed ID: 2190604
[TBL] [Abstract][Full Text] [Related]
26. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
27. CD4 activation of HIV fusion.
Sattentau QJ
Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
Yuan W; Bazick J; Sodroski J
J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
Sattentau QJ; Moore JP
J Exp Med; 1995 Jul; 182(1):185-96. PubMed ID: 7540648
[TBL] [Abstract][Full Text] [Related]
30. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
[TBL] [Abstract][Full Text] [Related]
31. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
McKeating JA; McKnight A; Moore JP
J Virol; 1991 Feb; 65(2):852-60. PubMed ID: 1898972
[TBL] [Abstract][Full Text] [Related]
32. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
33. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL
Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
McKeating JA; Cordell J; Dean CJ; Balfe P
Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
[TBL] [Abstract][Full Text] [Related]
35. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
36. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
[TBL] [Abstract][Full Text] [Related]
37. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
[TBL] [Abstract][Full Text] [Related]
38. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
39. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120.
Fu YK; Hart TK; Jonak ZL; Bugelski PJ
J Virol; 1993 Jul; 67(7):3818-25. PubMed ID: 8510207
[TBL] [Abstract][Full Text] [Related]
40. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
Bouma P; Leavitt M; Zhang PF; Sidorov IA; Dimitrov DS; Quinnan GV
J Virol; 2003 Jul; 77(14):8061-71. PubMed ID: 12829845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
